相似文献
1
Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.过继性细胞疗法——肿瘤浸润淋巴细胞、T细胞受体和嵌合抗原受体
Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12.
2
Improving the efficacy and safety of engineered T cell therapy for cancer.提高工程化 T 细胞疗法治疗癌症的疗效和安全性。
Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Epub 2012 Sep 27.
3
CAR T Cell Therapy for Solid Tumors.嵌合抗原受体 T 细胞疗法治疗实体瘤。
Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17.
4
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
5
Adoptive CD8 T cell therapy against cancer:Challenges and opportunities.过继性 CD8 T 细胞疗法治疗癌症：挑战与机遇。
Cancer Lett. 2019 Oct 10;462:23-32. doi: 10.1016/j.canlet.2019.07.017. Epub 2019 Jul 26.
6
Overcoming the toxicity hurdles of genetically targeted T cells.克服基因靶向 T 细胞的毒性障碍。
Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9.
7
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.使用肿瘤浸润性T细胞和基因工程化TCR-T细胞的T细胞过继性免疫疗法。
Int Immunol. 2016 Jul;28(7):349-53. doi: 10.1093/intimm/dxw022. Epub 2016 Apr 28.
8
Cancer immunotherapy using tumor antigen-reactive T cells.肿瘤抗原反应性 T 细胞的癌症免疫疗法。
Immunotherapy. 2018 Mar;10(3):235-245. doi: 10.2217/imt-2017-0130.
9
[T cell-based immunotherapies in solid tumors].[实体瘤中基于T细胞的免疫疗法]
Bull Cancer. 2021 Oct;108(10S):S96-S108. doi: 10.1016/j.bulcan.2021.06.004.
10
Cellular immunotherapy for malignant gliomas.恶性脑胶质瘤的细胞免疫治疗。
Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29.
引用本文的文献
1
A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies.嵌合抗原受体T细胞及过继性T细胞疗法在淋巴系统和实体器官恶性肿瘤中的研究综述
Med Sci Monit. 2025 Feb 2;31:e948125. doi: 10.12659/MSM.948125.
2
Efficacy of treatment with tumor-infiltrating lymphocytes as adoptive cell therapy: an integrative review.采用肿瘤浸润淋巴细胞进行过继性细胞治疗的疗效：一项综合性综述。
Einstein (Sao Paulo). 2024 Dec 16;22:eRW0935. doi: 10.31744/einstein_journal/2024RW0935. eCollection 2024.
3
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.硫酸软骨素蛋白聚糖4（CSPG4）作为治疗黑色素瘤免疫疗法的新兴靶点。
Cancers (Basel). 2024 Sep 25;16(19):3260. doi: 10.3390/cancers16193260.
4
The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma.大 T 抗原在 Merkel 细胞癌分子发病机制中的作用。
Genes (Basel). 2024 Aug 27;15(9):1127. doi: 10.3390/genes15091127.
5
Cancer immunotherapy and its facilitation by nanomedicine.癌症免疫疗法及其纳米医学促进作用。
Biomark Res. 2024 Aug 3;12(1):77. doi: 10.1186/s40364-024-00625-6.
6
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.超越免疫检查点抑制剂：黑色素瘤治疗中的新兴靶点。
Curr Oncol Rep. 2024 Jul;26(7):826-839. doi: 10.1007/s11912-024-01551-4. Epub 2024 May 25.
7
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.突变衍生的新抗原和非经典抗原与癌症治疗的相关性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2303799. doi: 10.1080/21645515.2024.2303799. Epub 2024 Feb 12.
8
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.攻克免疫迷宫：解除癌症免疫治疗耐药性的前沿策略
Cancers (Basel). 2023 Dec 15;15(24):5857. doi: 10.3390/cancers15245857.
9
Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.靶向黑素瘤相关抗原 CSPG4 的 HLA-C*07:01 限制性 T 细胞受体。
Front Immunol. 2023 Oct 2;14:1245559. doi: 10.3389/fimmu.2023.1245559. eCollection 2023.
10
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.诱导因子的表达重编程 CAR-T 细胞以增强功能和安全性。
Cancer Cell. 2022 Dec 12;40(12):1470-1487.e7. doi: 10.1016/j.ccell.2022.11.006.
本文引用的文献
1
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.用于治疗儿童和青年急性淋巴细胞白血病的表达CD19嵌合抗原受体的T细胞：一项1期剂量递增试验
Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.
2
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
3
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.化疗难治性弥漫性大B细胞淋巴瘤和惰性B细胞恶性肿瘤可以用表达抗CD19嵌合抗原受体的自体T细胞进行有效治疗。
J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.
4
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.一项评估 PRO131921（一种新型抗 CD20 单克隆抗体）在复发/难治性 CD20+惰性 NHL 患者中的安全性和药代动力学的 I 期临床研究：临床应答与 AUC 药代动力学的相关性。
Clin Immunol. 2014 Sep;154(1):37-46. doi: 10.1016/j.clim.2014.06.005. Epub 2014 Jun 11.
5
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.基于突变特异性 CD4+T 细胞的癌症免疫疗法在一名上皮癌患者中的应用。
Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.
6
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.PD-1 鉴定了浸润人类肿瘤的患者特异性 CD8⁺ 肿瘤反应性免疫组库。
J Clin Invest. 2014 May;124(5):2246-59. doi: 10.1172/JCI73639. Epub 2014 Mar 25.
7
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.间皮素特异性嵌合抗原受体 mRNA 修饰 T 细胞在实体恶性肿瘤中诱导抗肿瘤活性。
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
8
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
9
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.一项在转移性 CEA 表达癌成人中使用重组酵母-CEA 疫苗（GI-6207）的 I 期临床试验。
Cancer Immunol Immunother. 2014 Mar;63(3):225-34. doi: 10.1007/s00262-013-1505-8. Epub 2013 Dec 7.
10
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.表达组织驻留记忆标志物 CD103 的肿瘤浸润淋巴细胞与高级别浆液性卵巢癌患者生存率的提高相关。
Clin Cancer Res. 2014 Jan 15;20(2):434-44. doi: 10.1158/1078-0432.CCR-13-1877. Epub 2013 Nov 4.
Zotero 插件